Agios Pharmaceuticals, Inc. (AGIO) Stock Price & Analysis

Agios Pharmaceuticals, Inc. (AGIO) fell 0.09% to USD 33.1 as of September 8, 2026 at 04:19 UTC, according to Nexqual real-time market data.

AGIO last closed at USD 33.1; the session ranged USD 32.92–33.5 on volume of 480,161 shares. Market capitalization is —, with a 52-week range of USD 22.24–46 (NMS). Source: Nexqual, September 8, 2026 at 04:19 UTC.

Key Statistics (as of September 8, 2026 at 04:19 UTC)

Technical Analysis (AGIO)

Nexqual's technical model rates AGIO "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 04:19 UTC.

From Agios Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)

Key Strengths & Strategy (as disclosed to the SEC)

• We will have a pre-supplemental New Drug Application, or sNDA, meeting with the FDA in the first quarter of 2026 and intend to submit a U.S. marketing application for mitapivat in sickle cell disease, or SCD, following that engagement.
• Intellectual Property Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection for our product candidates and our core technologies, including novel biomarker and diagnostic discoveries, and other know-how, to operate without infringing on the proprietary rights of others and to prevent others from infringing on our proprietary or intellectual property rights.
• We also rely on confidential information, know-how, in-licensing opportunities and continuing technological innovation to develop and maintain our proprietary and intellectual property position.
• We seek to protect our proprietary information, in part, by using confidentiality agreements with our collaborators, third-party service providers, scientific advisors, employees and consultants, and by invention assignment agreements with our employees.

Partnerships

• Revenues associated with the NewBridge Agreement, the Avanzanite Agreement and the for charge portion of our global managed access program are included in the rest of world product revenue line within R esults of O perations .
• Also, in July 2023, we entered into a license agreement with Alnylam for the development and commercialization of products containing or comprised of an siRNA preclinical development candidate discovered by Alnylam and targeting the TMPRSS6 gene, and we are developing a product candidate, AG-236, for the potential treatment of patients with PV.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:19 UTC. This page is informational and not investment advice.